Marketing authorisation application for sotorasib submitted to European Medicines Agency for review

This KRAS inhibitor will be reviewed for use in previously-treated KRAS G12C-mutated non-small cell lung cancer. The application is supported by data from a phase II study, CodeBreaK 100, which is evaluating use after failure of a median of two prior lines of therapy.

PharmaTimes